Effective screening of infectious diseases requires a fast, cheap, and population-scale testing. Antigen pool testing can increase the test rate and shorten the screening time, thus being a valuable approach for epidemic prevention and control. However, the overall percent agreement (OPA) with polymerase chain reaction (PCR) is one-half to three-quarters, hampering it from being a comprehensive method, especially pool testing, beyond the gold-standard PCR. Here, a multiantibodies transistor assay is developed for sensitive and highly precise antigen pool testing. The multiantibodies capture SARS-CoV-2 spike S1 proteins with different configurations, resulting in an antigen-binding affinity down to 0.34 fM. The limit of detection reaches 3.5 × 10^–17 g mL^–1SARS-CoV-2 spike S1 protein in artificial saliva, 4–5 orders of magnitude lower than existing transistor sensors. The testing of 60 nasopharyngeal swabs exhibits ∼100% OPA with PCR within an average diagnoses time of 38.9 s. Owing to its highly precise feature, a portable integrated platform is fabricated, which achieves 10-in-1 pooled screening for high testing throughput. This work solves the long-standing problem of antigen pool testing, enabling it to be a valuable tool in precise diagnoses and population-wide screening of COVID-19 or other epidemics in the future.

中文翻译：

---

通过多抗体晶体管测定法进行超精密抗原 10 合 1 池检测

传染病的有效筛查需要快速、廉价和人口规模的检测。抗原池检测可以提高检测率，缩短筛查时间，是一种有价值的疫情防控手段。然而，聚合酶链反应 (PCR) 的总体一致性百分比 (OPA) 为二分之一到四分之三，这阻碍了它成为超越黄金标准 PCR 的综合方法，尤其是池检测。在这里，开发了一种多抗体晶体管检测，用于灵敏和高度精确的抗原池测试。多抗体捕获具有不同配置的 SARS-CoV-2 刺突 S1 蛋白，导致抗原结合亲和力低至 0.34 fM。检测限达到 3.5 × 10 ^–17 g mL ^–1SARS-CoV-2 在人工唾液中刺突 S1 蛋白，比现有的晶体管传感器低 4-5 个数量级。在平均 38.9 秒的诊断时间内，60 个鼻咽拭子的检测显示出约 100% 的 OPA 和 PCR。由于其高度精确的特性，制造了一个便携式集成平台，实现了高测试吞吐量的 10 合 1 汇集筛选。这项工作解决了长期存在的抗原池测试问题，使其成为未来 COVID-19 或其他流行病的精确诊断和全人群筛查的宝贵工具。